enfortumab vedotin
astellas,seagen
['bladder', 'enfortumab']
. will present 1:15pmcst today at #asco22 on antitumor activity of neoadjuvant treatment with enfortumab vedotin monotherapy in patients w/muscle-invasive bladder cancer who are cisplatin-ineligible. 
Yale Cancer Center is a collaboration between renowned cancer researchers and physicians @Yale and @SmilowCancer.